Well Done LLC Sells 148 Shares of Eli Lilly and Company (NYSE:LLY)

Well Done LLC cut its position in Eli Lilly and Company (NYSE:LLY) by 37.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 243 shares of the company’s stock after selling 148 shares during the quarter. Well Done LLC’s holdings in Eli Lilly and Company were worth $215,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company during the second quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new stake in Eli Lilly and Company during the second quarter worth approximately $36,000. Redmont Wealth Advisors LLC bought a new position in Eli Lilly and Company during the 1st quarter worth $40,000. Morton Brown Family Wealth LLC lifted its position in shares of Eli Lilly and Company by 45.5% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after acquiring an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC grew its holdings in shares of Eli Lilly and Company by 53.3% during the 3rd quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock worth $41,000 after purchasing an additional 16 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. JPMorgan Chase & Co. boosted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Sanford C. Bernstein started coverage on shares of Eli Lilly and Company in a report on Thursday. They set an “outperform” rating and a $1,100.00 price target for the company. Morgan Stanley reissued an “overweight” rating and issued a $1,106.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $986.00.

Eli Lilly and Company Trading Up 0.1 %

Shares of NYSE LLY opened at $917.86 on Friday. The stock has a market cap of $872.34 billion, a P/E ratio of 135.18, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The firm has a 50 day moving average price of $921.21 and a two-hundred day moving average price of $857.37. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. As a group, equities analysts forecast that Eli Lilly and Company will post 16.49 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.